drugset / Trial / NCT00534378
Phase I Trail for Intramuscular Administration of Midazolam Using An Autoinjector
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Purpose of the study is to determine midazolam's safety and dose-linearity when delivered intramuscularly via an autoinjector. The proposed initial treatment dosage for seizures induced by exposure to nerve agents.
Timeline
- Start
- 2006-07
- Primary completion
- —
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Midazolam | Small molecule | 0.1 mg/kg | Intramuscular |
| Comparator | Midazolam | Small molecule | 0.18 mg/kg | Intramuscular |
| Comparator | Midazolam | Small molecule | 0.25 mg/kg | Intramuscular |
| Comparator | Midazolam | Small molecule | 0.33 mg/kg | Intramuscular |
| Comparator | Midazolam | Small molecule | 0.4 mg/kg | Intramuscular |
| Comparator | Midazolam | Small molecule | 0.49 mg/kg | Intramuscular |